Insights
Search Results
Client Highlights
2.26.26
Wilson Sonsini Advises Eventus on Majority Investment by Terminus Capital Partners
On February 26, 2026, Terminus Capital Partners (TCP), a growth‑oriented private equity firm focused on majority investments in B2B software companies, and Eventus, a leading provider of comprehensive, at-scale trade surveillance and financial risk solutions, announced that TCP has acquired majority control in Eventus, positioning the firm for accelerated geographical expansion and growth in its product offerings. Wilson Sonsini Goodrich & Rosati advised Eventus on the transaction.
Client Highlights
9.25.25
Wilson Sonsini Advises LALO Tequila on Acquisition by Tito’s
On September 23, 2025, Tito's Handmade Vodka, the brand behind Texas' first legal distillery and the award-winning vodka, announced it has entered into a definitive agreement to acquire the majority stake in LALO Tequila, one of the fastest-growing tequila brands in the United States. Wilson Sonsini Goodrich & Rosati advised LALO on the transaction.
Client Highlights
7.25.25
Wilson Sonsini Advises Revival on Strategic Partnership with Olympus
On July 25, 2025, Revival Healthcare Capital (Revival), an investment firm focused on transformative external innovation partnerships in MedTech, announced a strategic partnership with Olympus Corporation (Olympus), a global healthcare leader committed to making people’s lives healthier, safer, and more fulfilling through advanced medical technologies and solutions. The partnership is aimed at harnessing external innovation to accelerate development and market entry for an endoluminal robotics platform initially targeting gastrointestinal (GI) treatments. Wilson Sonsini Goodrich & Rosati advised Revival on the transaction and on fund matters related to the transaction.
Client Highlights
9.10.24
Wilson Sonsini Represents Syxsense in its Acquisition by Absolute Security
On September 5, 2024, Absolute Security, a Seattle, WA-based company which specializes in enterprise cyber resilience, acquired Syxsense, an innovator in automated endpoint and vulnerability management. The amount of the deal was not disclosed. Wilson Sonsini Goodrich & Rosati advised Syxsense on the transaction.
Press Releases
12.04.23
Wilson Sonsini Goodrich & Rosati Elects 20 New Partners
Contact:
Kimberly Brooks
Wilson Sonsini
+1 212.453.2881
kbrooks@wsgr.com
Kimberly Brooks
Wilson Sonsini
+1 212.453.2881
kbrooks@wsgr.com
Client Highlights
2.08.22
Wilson Sonsini Advises GeoPhy on $85 Million Acquisition by Walker & Dunlop
On February 7, 2022, Walker & Dunlop announced it has entered into a definitive agreement to acquire GeoPhy, a leading commercial real estate technology company. GeoPhy's data analytics and development capabilities will dramatically accelerate the growth of Walker & Dunlop's lending, brokerage, and emerging businesses including Apprise, its tech-enabled appraisal business and its small balance lending (SBL) platform. Under the terms of the purchase agreement, Walker & Dunlop will acquire GeoPhy for $85 million in cash to be paid at closing with an additional $205 million of cash earn-out potential structured to directly align with Walker & Dunlop's "Drive to '25" goals surrounding growth in appraisal revenues, SBL volumes, and mortgage banking gains, as detailed in the company press release.
Client Highlights
3.24.21
Wilson Sonsini Advises Everlywell on Acquisition of PWNHealth and Home Access Health Corporation
On March 24, 2021, Everlywell, a leading digital health company, announced that it has acquired PWNHealth and Home Access Health Corporation and formed parent company Everly Health. Together, the combined companies support more than 20 million people annually in all 50 U.S. states, Canada, and Puerto Rico. Wilson Sonsini Goodrich & Rosati is advising Everlywell on the transaction.
Headquartered in Austin, Texas, Everly Health is committed to transforming lives through high-quality diagnostic care with a user-first digital experience. The acquisition will enable the companies to scale their respective services while maintaining a strong commitment to data privacy and clinician independence. PWNHealth will be rebranded as Everly Health Solutions and operate as an independent subsidiary of Everly Health, maintaining complete data independence from Everlywell.
Overall, Everly Health now employs nearly 500 people, has an extensive telehealth network covering all 50 states, and has over 350 clients, including many of the largest health plans, employers, and labs in the United States.
Founded in 2015, Everlywell provides Americans with access to more than 35 home collection lab tests, sold online and in major retailers such as Target, CVS, and Walgreens. In May 2020, the company became the first digital health company to receive FDA authorization for a mail-in COVID-19 test and is one of the first companies to receive "direct to consumer" (DTC) authorization from the FDA for its COVID-19 Test Home Collection Kit DTC. Everlywell saw over 300 percent growth in the last year, showing the rising tide of consumer demand for accessible, affordable testing long after doctor's offices and clinics have largely resumed normal services.
The Wilson Sonsini team advising Everlywell on the transaction includes:
Corporate/M&A
Brandon Middleton-Pratt
Melanie Froh
Headquartered in Austin, Texas, Everly Health is committed to transforming lives through high-quality diagnostic care with a user-first digital experience. The acquisition will enable the companies to scale their respective services while maintaining a strong commitment to data privacy and clinician independence. PWNHealth will be rebranded as Everly Health Solutions and operate as an independent subsidiary of Everly Health, maintaining complete data independence from Everlywell.
Overall, Everly Health now employs nearly 500 people, has an extensive telehealth network covering all 50 states, and has over 350 clients, including many of the largest health plans, employers, and labs in the United States.
Founded in 2015, Everlywell provides Americans with access to more than 35 home collection lab tests, sold online and in major retailers such as Target, CVS, and Walgreens. In May 2020, the company became the first digital health company to receive FDA authorization for a mail-in COVID-19 test and is one of the first companies to receive "direct to consumer" (DTC) authorization from the FDA for its COVID-19 Test Home Collection Kit DTC. Everlywell saw over 300 percent growth in the last year, showing the rising tide of consumer demand for accessible, affordable testing long after doctor's offices and clinics have largely resumed normal services.
The Wilson Sonsini team advising Everlywell on the transaction includes:
Corporate/M&A
Brandon Middleton-Pratt
Melanie Froh
Client Highlights
12.03.20
Wilson Sonsini Advises Everlywell on $175 Million Series D Financing
On December 3, 2020, Everlywell, a leading digital health company, announced an oversubscribed Series D financing of $175 million. New investors participating in the round include funds and accounts managed by BlackRock, The Chernin Group (TCG), Foresite Capital, Greenspring Associates, Lux Capital, Morningside Ventures, and Portfolia, as well as existing investors Goodwater Capital, Highland Capital Partners, and Next Coast Ventures. This investment brings the total capital raised by the company to over $250 million, which includes a Series C round led by Highland Capital Partners earlier this year. Wilson Sonsini advised Everlywell in connection with the financing.
"The pandemic has shed light on the challenges of lab testing for Americans, from unknown costs to confusion and inconvenience. We've been empowering people with a new way to get tested for five years and will continue to lead the way in a rapidly expanding space," said Julia Cheek, Everlywell founder and CEO. "We believe lab testing will be rapid, simple, and coupled with virtual care in the near future. This partnership with additional world-class investors enables us to build a transformative, multi-generational digital health company that puts people first—where they belong."
"The pandemic has shed light on the challenges of lab testing for Americans, from unknown costs to confusion and inconvenience. We've been empowering people with a new way to get tested for five years and will continue to lead the way in a rapidly expanding space," said Julia Cheek, Everlywell founder and CEO. "We believe lab testing will be rapid, simple, and coupled with virtual care in the near future. This partnership with additional world-class investors enables us to build a transformative, multi-generational digital health company that puts people first—where they belong."